The outcome of patients with AML in Morocco is poor. The major causes of failure are delay in diagnosis, early (prior to start of therapy) and induction deaths, induction failures and abandonment of therapy. This study aims to improve overall and event free survival for patients with favourable risk AML in Morocco through intensification of therapy along with improvement in supportive care. Moreover, epidemiologic data on the frequency of the favourable translocations will be obtained.
Impact
The study improved diagnostics esp. cytogenetics (from earlier coverage of 53% to now 97% patients have cytogenetics testing) and immunophenotyping (from earlier coverage of 53% to now 93% coverage of patients) Development of infection control infrastructure with education to health care professionals (HCP), patients and families. Development of Hospital Acquired Infection (HAI) program Improvement in diagnosis of infection. No therapy abandonment CVL use and care Training of personnel
Student Experience
Education of residents and fellows at the two sites in Morocco Local resident/fellow Participation in research
Countries
Canada, Monaco, Morocco, United States of America
Impact
Research, Education, Global Partnerships
Institutional Partner(s)
St Jude Children's Reserach Hospital, Service d Hematologie et d’oncologie Pediatrique, Casablanca, Morocco, Unite d Hemato-Oncologie Pediatrique, Rabat, Morocco
Community Partner(s)
Industry Partner(s)
Key Outcomes
Publications
Sponsorship
Foreign
Sponsorship Details
Direction De la Cooperation Internationale (DCI) Principaute de Monaco St Jude Children’s Research Hospital
